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Summary 
Humanized IgG1 M195 (HuG1-M195), a complementarity determining region-grafted recombinant 
monoclonal antibody, is reactive with CD33,  an antigen expressed on myelogenous leukemia 
cells.  M195 is in use in trials for the therapy of acute myelogenous leukemia.  Since biological 
activity of IgG may depend, in part, on multimeric Fab and Fc clustering, homodimeric forms 
of HuG1-M195 were constructed by introducing a mutation in the 3'1 chain CH3 region gene 
to change a serine to a cysteine,  allowing interchain  disulfide bond formation  at  the COOH 
terminal of the IgG. Despite similar avidity, the homodimeric IgG showed a dramatic improvement 
in the ability to internalize and retain radioisotope in target leukemia cells, Moreover, homodimers 
were 100-fold more potent at complement-mediated leukemia cell killing and antibody-dependent 
cellular cytotoxicity using human effectors. Therefore, genetically engineered multimeric constructs 
of IgG may have  advantages relative to those forms that  are found naturally. 
C 
DR-grafted humanized mAbs have been constructed to 
improve immunological effector functions and reduce 
immunogenicity (1-5). The production of a CDR-grafted, 
humanized IgG1 construct (HuG1-M195) of the mouse M195 
antibody, an anti-CD33 mAb that is specifically reactive with 
acute myelogenous leukemia (AML) cells and early myeloid 
progenitors, but not hematopoietic stem cells, has been de- 
scribed (6-9). M195 is currently being evaluated in the therapy 
of AML (10, 11). HuG1-M195 retains specificity of binding, 
the capability of internalization  into  HL60 leukemia cells, 
and the ability to fix human complement (7).  In addition, 
HuG1-M195 shows superiority over its murine counterpart 
in its higher  avidity and new ability to perform antibody- 
dependent cellular cytotoxicity (ADCC) with human effector 
cells  against  acute myelogenous leukemia cells (7). 
The biological activities of IgG depend,  in part,  on the 
ability to crosslink antigen  on the cell surface and to bind 
complement or Fc receptors on effector cells via muhivalent 
interactions. Recently, the genetic engineering of a chimeric 
IgG reactive with a hapten to form a mutant  Ig linked to- 
gether as a covalent dimer, resulted in enhanced complement 
mediated cytotoxicity (CMC) (12). In an attempt to improve 
the CMC as well as other biological and immunological prop- 
erties of the humanized M195 mAb, similar homodimers (Hd- 
IgG) were genetically designed. A mutation at the COOH 
end of the CH3 domain of the 71 H  chain was introduced 
in HuG1-M195 that results in enhanced CMC,  and also a 
dramatic improvement in the ability to perform ADCC against 
leukemic target ceils.  In addition,  the Hd-IgG shows more 
rapid modulation with markedly improved retention of tar- 
geted radioisotope within the target cells. These Hd-IgG may 
have therapeutic  applications. 
Materials and Methods 
Construction of Homodimeric IgG (Hd-IgG).  The construction 
of vectors to express humanized  M195 L and H chains has been 
described (6). For expression of Hd-IgG, the H chain expression 
vector was mutagenized by changing the codon TCT to TGT which 
resulted in converting amino acid at position 444 of H chain from 
Ser to Cys (Fig. 1 A). The cys allows interchain disulfide bond for- 
mation which  allows expression of Hd-IgG (Fig. 1 B). To allow 
formation of Hd-IgG, 87 mg of mAb was purified from culture 
supernatant and concentrated to 10 mg/ml in 0.1 M Tris, pH 8.6. 
4 mg of EUman's reagent (Pierce Chemical Co., Rockford, IL) was 
added and incubated at room temperature for 1 h to crosslink and 
then block the excess sulfhydryl sites. The sample was adjusted to 
2.5 M NaC1 and loaded onto a 50-ml phenyl-Sepharose column 
equilibrated with 2.5 M NaCI. Monomer antibody was eluted off 
the column  in PBS. Crosslinked material  (Hd-IgG) were eluted 
in 50% propylene glycol in water. SDS-PAGE analysis showed the 
dimers to be 90% pure. 
Cell Surface Modulation.  5  ￿  10  ~ HL60 cells were incubated 
at 37~  with 2/~g/ml of HuG1-M195 or Hd-IgG, and aliquots 
were taken at 0, 60, 150, and 300 rain. The cells were washed twice 
in RPMI and pelleted at 500 g, and 50 #1 of goat anti-human fluores- 
cein conjugate was added for 30 rain, followed by washing twice, 
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Figure 1.  (/1)  Sequence at the site of the mutation of the constant re- 
gion of the plasmid allowing interchain disulfide  bond formation. (B) Di- 
agram of homodimeric-HuG1-M195  (Hd-IgG), 
and fixing in 0.5%  paraformaldehyde before analysis. Ten thou- 
sand cells were analyzed on an Epics profile flow cytometer (Coulter 
Electronics Inc., Hialeah, FL), and the mean fluorescent intensity 
was  measured.  Hematopoietic cell  lines  were grown in  RPMI 
1640/5% newborn calf serum/10% serum-plus (Hazleton Biologics, 
Inc., Lenexa, KS). 
Internalization Studies.  HuG1-M195 or Hd-IgG were labeled 
with Na-nSI  (New England Nuclear, Boston, MA) as described 
previously (8). Internalization of the HuG1-M195 or Hd-IgG was 
measured from 0 to 48 h by incubating 0.01-2/~g/ml of radiola- 
beled mAb with  1-2  x  10  + HL60 cells/ml in RPMI  1640/2% 
human Ab serum. Cells were then washed twice in RPMI, and 
the surface-bound M195 was stripped with 1 ml of 50 mM gly- 
cine/150 mM NaC1, pH 2.8 at 24~  for 10 rain. The amount (ng) 
of mAb per million cells remaining after the acid wash (i.e., inter- 
nalized),  or in the supernatant (i.e., cell surface) is shown. 
CMC.  For CMC assays, 25/~1 of 5  x  106 HL60 cells/ml were 
incubated with 25/~1 of diluted rabbit complement and 25 #1 of 
serial dilutions of HuG1-M195 or Hd-IgG at 37~  for 1 h. mAb 
M31 (IgM anti-CD15) was used as a positive control. Live and dead 
cells were enumerated using trypan blue. Low toxicity rabbit serum 
was purchased from Pel-Freeze (Rogers, AR). Complement was 
used at the maximum concentrations not showing nonspecific lysis 
of the target cells, usually from 1:6 to 1:9 final dilution. 
ADCC.  Chromium release assays were conducted using PBMC 
from human volunteers as effector cells and HL60 cells as positive 
targets.  Target cells were incubated in SlCr for 90 rain and then 
washed of free SlCr. HuG1-M195 or Hd-lgG was added at E/T 
ratios of 10:1, 25:1, and 100:1. Cells were incubated at 37~  for 
5 h and harvested using a cell harvester (Skatron, Inc., Sterling, 
VA), and released SlCr was counted in a gamma counter (Packard 
Instrument Co., Downers Grove, IL). Detergent-lysed cells were 
used as a 100% control. Effector cell only and mAb only treated 
target cells were used as negative controls. Samples were done in 
quadruplicate, and SD were always <10% of the mean value. Specific 
lysis =  A  -  C/B  -  C; where: A  =  cpm release in the presence 
of mAb;  B  =  total cpm released  by detergent lysed cells;  and 
C  =  cpm released in the presence of medium alone. 
Results  and  Discussion 
The ability of Hd-IgG to bind to CD33 expressing HL60 
cells was determined by radiobinding assays in the presence 
of excess HL60 cells, as described previously (8).  Total im- 
munoreactivity (the fraction of the total radiolabeled Ig capable 
of binding  to antigen)  of Hd-IgG nearly doubled to 85% 
as compared with 50%  for the HuG1 in these assays.  The 
increased immunoreactivity may relate to the presence of mul- 
tiple binding sites that were less likely to be inactivated by 
radiolabeling. Direct radioimmunoassay showed that binding 
of both constructs to HL60 cells was saturable and specific. 
Scatchard analysis of HuG1-M195  showed a slightly lower 
avidity of binding (K~  =  4.4  x  109 M- t) than that of Hd- 
IgG(Ka  =  6.1  x  109M-1). 
Since direct radiobinding can be affected by damage to the 
mAb generated during the radioiodination of the Ig, the rel- 
ative avidities of the HuG1-M195 and Hd-IgG were also com- 
pared by competition assays  on HL60 cells in the presence 
of human serum to prevent nonspecific and human Fc receptor 
binding,  as  described  previously  (7).  These  experiments 
confirmed the Scatchard analysis that  the binding  acidities 
of Hd-IgG and HuG1-M195  were similar. 
Cell surface modulation with subsequent internalization 
of M195 antibody and conjugated isotope has been seen in 
vitro and in vivo in patients,  and is an important aspect of 
its therapeutic effect in humans for the treatment  of AML 
(10,  11).  Although Hd-IgG bound to the cell surface with 
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Figure 2.  (.'t) Indirect flow cytometric analysis comparing cell surface 
modulation of HuG1-M195 (lB---IB) vs Hd-IgG (O---O) over 5 h. (B) 
Internalization and retention of HuG1-M195 in radiobinding experiments 
on HL60 cells at 37~  over 6 h. Cell surface  HuG1 (IB---lB); cell surface 
Hd-IgG  (O--'O);  internalized HuG1  (B'-B);  internalized Hd-IgG 
(O--O). Radiolabeled mAb at a final concentration of 2/~g/ml was in- 
cubated at 370C with 106 HL60 cells/ml in a total volume of 200/zl. In- 
ternalization was measured as described in the text. Each time point was 
done in duplicate, and these results are representative  of three independent 
experiments. 
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merization of the mAb might alter its ability to modulate. 
The kinetics of modulation were examined by indirect fluores- 
cence flow cytometry on HL60 cells. HuG1-M195 accumu- 
lated on the surface of HL60 cells  to reach a peak at  1 h, 
and then slowly modulated (Fig. 2 A). By 5 h, 40% of HuG1 
remained on the cell surface￿9 In contrast, Hd-IgG was im- 
mediately modulated from the cell surface without accumu- 
lation first, with 12% of the mAb remaining on the cell sur- 
face at 5 h.  Thus, Hd-IgG modulated much faster and to 
a greater degree than HuG1-M195, apparently without re- 
quiting the threshold of  binding shown by the HuG1-M195. 
The fates of the rapidly modulated Hd-IgG and HuG1- 
M195 were evaluated in the same time period, and internali- 
zation was measured by acid washing the cells at various times 
after t2SI-mAb binding to remove residual cell surface mAb 
(Fig. 2 B). Studies done at 0~  showed that neither HuG1- 
M195 nor Hd-IgG entered the cell.  At 37~  the Hd-IgG 
at 2 #g/ml rapidly entered the intracellular compartment, 
with 70% of the radiolabeled mAb being retained inside the 
cell, and 30% staying on the surface. In contrast, only 30-40% 
of the HuG1-M195 was retained inside the cell over the same 
time period with the remainder on the surface￿9 
An extended analysis of internalization out to 48 h showed 
persistence of the Hd-IgG within cells (Fig.  3). In contrast, 
HuG1 demonstrated the same pattern of limited internaliza- 
tion as seen in Fig. 2 (not shown). Thus, the rapid modula- 
tion resulted in efficient internalization of the radiolabeled 
Hd-IgG into the cell, and, most importantly, the Hd-IgG 
was not lost from the cell over long time periods. 
Based on integration (areas under the curves) of these in- 
ternalization data,  radiation doses delivered by Hd-IgG to 
the inside of the cells was more than double that of HuG1 
by 48 h. Therefore, presumably in vivo, total radiation doses 
to target cells would be twice as high for the same added 
dose and same toxicity. The differences in internalization ki- 
netics may be attributed to the immediate clustering of CD33 
achieved by the multivalent Hd-IgG.  Such clustering may 
require time to accumulate with Hug1-M195, thus accounting 
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Figure 3.  The amounts of radiolabded Hd-IgG remaining on the sur- 
face (ni...i) and internalized  (I~--M) over  48 h. Radiolabeled  Hd-IgG 
at 1/zg/ml was incubated  at 37~  with 2 x  106 HL60 cells/m1 in a final 
volume of 200/zl, and internalization  was measured as described in the 
text. Each time point was done in triplicate and SD was <10%. 
Table  1.  Percent  Internalization of HuGI  and Hd-IgG 
Percent internalization* 
mAb  Concentration  HuG1  Hd-IgG 
nM 
6.70  43  67 
2.23  40  70 
0.74  39  64 
0.25  41  58 
0.08  38  45 
* Radiolabeled mAb at concentrations  shown were incubated with 2 x 
106 HL60 cells at 37~  for 4 h in a total volume  of 200/~1. Internaliza- 
tion was measured as described in the text. Each time point was done 
in triplicate and SD was <10% of the mean. 
for the threshold effect, the delay in internalization, and the 
poor effciency. 
To determine whether mAb concentration affected inter- 
nalization, HuG1 and Hd-IgG at similar molar concentra- 
tions were incubated with HL60 cells for 4 h at 37~  Hd-IgG 
showed greater internalization than HuG1 at every concen- 
tration (Table 1). Whereas the total amount of bound radio- 
activity varied with the concentration of mAb added (not 
shown),  the percentage of internalization of mAb did not 
change over the 2-log range of mAb concentrations￿9 Thus, 
except possibly at very low concentrations, the percentage 
of either HuG1 or Hd-IgG internalized into HL60 cells was 
not dependent on mAb dose. 
Although others (13-15) have found that crosslinked IgG 
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Figure 4.  ADCC  of HuG1-M195 and Hd-IgG is shown as a function 
of  concentration  and E/T ratio. Target  HL60 cells  were  incubated  at 37~ 
with mAb and PBMC as effectors,  and slCr-release  was measured  5-h later 
as described  in the text. Hd-IgG was 100-fold  more potent (50 times on 
a weight basis) and 2-6 times more effective  than the HuG1-M195 at 
ADCC. Hd-IgG at 0.2 ~g/ml (D); Hd-IgG at 1 /tg/ml (In); Hd-IgG 
at 10 #g/ml (~); HuG1-M195  at 0.2 #g/ml (~); HuG1-M195  at 1/~g/ml 
(f~); HuG1 at 10/~g/ml ([~). Results shown are from a representative 
experiment that was repeated on three separate days. 
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via specific Fab binding to antigen and not to Fc receptors. 
The metabolism of Ig after Fc receptor-mediated internaliza- 
tion has been reported to be both increased and decreased 
by oligomerization (13, 16,  17). 
Hd-IgG was at least 100-fold more potent on a molar basis 
at cell killing with rabbit complement than the HuG1-M195 
(not shown). In this and other experiments, no cytotoxicity 
of HuG1-M195 was seen below a concentration of .01 gg/ml, 
whereas Hd-IgG demonstrated a linear increase in cell lysis 
starting at .001 #g/ml. Since both HuG1-M195 and Hd-IgG 
have similar avidities of binding, this would not explain the 
enhanced ability of Hd-IgG to perform CMC. Moreover, the 
more rapid and efficient  internalization of Hd-IgG would argue 
against its improved ability to perform CMC, since less mAb 
would be available on the cell surface to fix complement. Al- 
though HuG1-M195 (7) and Hd-IgG were capable of fixing 
human complement and killing AL67 fibroblasts that over- 
express CD33, neither HuG1-M195 nor Hd-IgG lysed HL60 
cells in the presence of human serum. 
Several lines of evidence suggest that the proximity of Fc 
regions of multimeric IgG may explain its enhanced effec- 
tiveness in CMC as compared with monomeric IgG. Binding 
and activation of Clq requires the formation of doublet IgG 
on the cell surface (18). Since Hd-IgG intrinsically contains 
a doublet of Fc regions, it may allow more efficient binding 
of the polyvalent Clq.  The concept that a duster of IgGs 
allows for multiple points of C1 attachment (19-21) is con- 
sistent with our observations of enhanced CMC here. It has 
been suggested that another site of attachment to the CH1 
domain is needed (22). Hd-IgG may facilitate such spatial 
rearrangements.  Bispecific antibodies capable of binding to 
two antigens (23) and a chimeric antibody with dual Fc regions 
(24) were superior to conventional IgG in CMC, presum- 
ably because of the increased number of Fc regions and their 
close arrangement in pairs. A critical number of antigen sites 
or critical spacing of epitopes on the cell surface has been 
shown to be necessary for CMC to occur with monovalent 
IgG (7, 25, 26). Naturally occurring IgG3 mAbs to carbo- 
hydrate antigens, which exhibit intermolecular cooperativity 
through Fc region interactions,  show potent complement- 
mediated effector functions (27). The Hd-IgG described here 
may achieve this via a genetic mechanism. 
Hd-IgG was at least 100 times more potent on a molar 
basis than HuG1-M195 at ADCC (Fig. 4). Specific  lysis with 
0.2 gg/ml Hd-IgG was as much as twofold greater than 10 
gg/ml HuG1-M195 at the same E/T ratios. Hd-IgG was two- 
to fivefold more effective over a 50-fold concentration range 
at each E/T ratio. Chimeric and humanized IgG have shown 
ADCC where the original murine mAb did not demonstrate 
that capability (28-30). It is not surprising that homodimeric 
humanized IgG would be even more effective than mono- 
meric IgG because of the greater ability of dual Fc regions 
to bring together effectors and targets in close proximity to 
allow ADCC to occur. I1,2 has been shown to potentiate 
ADCC against human Tac-positive T cells with humanized 
anti-Tac mAb (28). We have evidence that II.-2 enhances both 
HUG1- and Hd-IgG-mediated ADCC against HL60 target 
cells (31). The combination of other cytokines and Hd-IgG 
to enhance effector cell function needs to be investigated. 
Previously, a human polymeric IgG1 mAb against group 
B streptococcus, held together by noncovalent interactions, 
has been described which showed enhanced binding and op- 
sonic activity compared with the original monomeric mAb 
(32). The demonstrated homophih'c interactions with a mouse 
IgG3 mAb, R24, reactive with GD3 ganglioside, have also 
led to the suggestion  that multimerization of Ig may be a 
mechanism to enhance antibody-mediated  clearance of bac- 
teria (33). 
The improvement in internalization of homodimeric  M195 
IgG should be advantageous for its use as a carrier of radio- 
labels or toxins, and should allow the delivery of more cyto- 
toxic agent to target cells for each injected dose. Although 
we are currently able to safely deliver therapeutic levels of 
radioisotope to leukemia cells in humans in vivo, this change 
in cellular kinetics should allow the same therapeutic effects 
with less injected dose. In addition,  the markedly improved 
effector functions and potency of Hd-IgG alone seen in vitro 
may result in potentially effective cytotoxicity against AML 
in vivo without conjugated cytotoxins  or isotopes. 
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